Bruker Corporation — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; financial statements are unaudited. Bruker develops and sells scientific instruments and analytical and diagnostic solutions through BSI Life Science, BSI NANO and BEST.
Key financial results
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $554.7 million | $424.0 million | +30.8% |
| Gross profit / margin | $278.7 million / 50.2% | $192.3 million / 45.4% | Margin +4.8 percentage points |
| Operating income / margin | $89.1 million / 16.1% | $16.4 million / 3.9% | Margin +12.2 percentage points |
| Net income attributable to Bruker | $56.7 million | $10.5 million | +440.0% |
| Diluted EPS | $0.37 | $0.07 | +$0.30 |
| Cash from operations | $98.0 million | $35.0 million | +$63.0 million |
| Free cash flow | $73.3 million | $4.5 million | +$68.8 million |
Reported revenue growth included approximately $26.8 million from foreign currency translation and $3.2 million from acquisitions; organic revenue, a non-GAAP measure, increased $100.7 million. Management attributed improved profitability to higher revenue and volume, operating leverage, and a richer product mix. Non-GAAP gross margin was 51.3% versus 46.7%; non-GAAP operating margin was 18.4% versus 7.6%.
Revenue by reportable segment
| Segment | Q1 2021 revenue | Year-over-year change |
|---|---|---|
| BSI Life Science | $351.8 million | +34.6% |
| BSI NANO | $154.4 million | +28.6% |
| BEST | $52.4 million | +13.4% |
Life Science benefited from demand for mass spectrometry, infrared and Raman products, recovering NMR demand and deliveries, including two GHz-class NMR systems. NANO growth reflected recovering industrial and academic demand and strength in semiconductor and microelectronics customers. BEST growth reflected project completions.
Liquidity, debt and capital allocation
- At March 31, cash and cash equivalents were $696.8 million and short-term investments were $50.0 million, totaling $746.8 million. Cash, equivalents and short-term investments were $731.8 million at year-end 2020.
- Total debt was $824.2 million, down from $844.5 million at December 31, 2020. The current portion rose to $108.4 million from $2.2 million, while long-term debt fell to $715.8 million from $842.3 million. The filing does not explain this classification change in the provided text.
- Nearly $599.8 million remained available under the $600 million revolving credit agreement; no borrowings were outstanding. Bruker reported compliance with debt covenants and expected cash and credit facilities to cover operating and investing needs for at least 12 months.
- Q1 cash uses included $24.7 million of capital expenditures, $32.6 million of share repurchases and $6.1 million of dividends. The $300 million repurchase program was completed in April 2021.
Outlook, risks and unusual items
- Outlook: Bruker warned that COVID-19 and challenges to customer and company operations may negatively affect Q2 2021 results. It did not provide a clear full-year revenue or earnings forecast in the filing text. Remaining performance obligations were approximately $1.94 billion; about 65.7% was expected to be recognized as revenue over the next 12 months.
- COVID-19 and supply chain: Resurgence, new virus strains, restrictions, delayed installations and customer spending constraints could affect demand and execution. Semiconductor and other component shortages could constrain manufacturing and deliveries.
- Tax: The effective tax rate increased to 32.2% from 21.5%, attributed primarily to jurisdictional earnings mix and unfavorable discrete items.
- Legal settlement: Bruker settled patent litigation with Micromass, agreeing to a $4.0 million upfront payment in Q2 2021 and royalties, subject to a quarterly minimum, on certain timsTOF systems beginning March 2022. The company said the settlement was not expected to materially affect results. A separate Zeiss-related patent claim was being vigorously defended.
- Other items: Q1 other charges were $3.0 million, including restructuring, acquisition-related and IT transformation costs. Foreign currency translation reduced comprehensive income, and exchange-rate effects reduced cash by $21.0 million.
- Management cited foreign exchange, interest rates, commodity prices, government and academic funding, customer ordering and installation timing, and global economic conditions as additional sources of variability.
Important facts for investors to verify
- Whether demand recovery and strong Q1 margins persist, particularly in Life Science and NANO, and how Q2 results compare with the company’s COVID-related warning.
- Whether supply shortages, delayed installations or customer spending constraints affect backlog conversion and the $1.94 billion of remaining performance obligations.
- The debt maturity and repayment implications of the increase in current debt to $108.4 million, alongside available revolver capacity and covenant compliance.
- The ultimate cost of the Micromass license, including future royalties, and developments in the ongoing Zeiss matter.
- Whether the higher effective tax rate and currency movements continue to affect earnings and reported cash flows.